Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma

Next Previous
Trial Profile

A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation

Most Recent Events

  • 28 Jan 2019 Status changed from active, no longer recruiting to completed.
  • 05 Mar 2018 Planned End Date changed from 1 Jun 2018 to 30 Jun 2018.
  • 06 Dec 2016 Primary endpoint (Objective Disease Response in accordance with International Workshop Response Criteria (IWC) 1999. Step 2) has been met, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top